Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling

Foretinib, a multiple kinase inhibitor undergoing clinical trials, could suppress the activity of hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor-2 (VEGFR-2). In addition, Foretinib may inhibit two critical lymphangiogenic signaling receptors VEGFR-3 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Hsiu-Mei, Tsai, Chia-Hua, Hung, Wen-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558127/
https://www.ncbi.nlm.nih.gov/pubmed/25909285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558127/
https://www.ncbi.nlm.nih.gov/pubmed/25909285

Ejemplares similares